Transplantation of insulin-producing cells purified from a donor pancreas is established within the NHS. This is restricted to people with life-threatening complications of type 1 diabetes as liberation from injected insulin cannot yet be guaranteed and life-long immunosuppression is needed. The potential for harnessing regenerative medicine and tissue engineering to deliver truly transformative outcomes is discussed.